

Ontario Public Drug Programs

Drug Submission Status

Report for May 2017

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mylan Pharmaceuticals ULC	Mylan-Atazanavir	Reyataz	atazanavir sulfate	300mg	capsule	02456893
Teva Canada Limited	Teva-Atazanavir	Reyataz	atazanavir sulfate	300mg	capsule	02443821